Safety of hydroxychloroquine for treatment or prevention of SARS‐CoV‐2 infection: A rapid systematic review and meta‐analysis of randomized clinical trials
Abstract Introduction Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID‐19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue. Methods In the face of controversial results about clinical e...
Main Authors: | Alberto Enrico Maraolo, Adriano Grossi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.374 |
Similar Items
-
New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine
by: Davide Gentile, et al.
Published: (2020-08-01) -
First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2
by: Y. Roussel, et al.
Published: (2020-11-01) -
Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus
by: Isabel Kinney Ferreira de Miranda Santos, et al.
Published: (2020-08-01) -
Cardiovascular safety of hydroxychloroquine: Brief appraisal of data
by: Anil Pareek, et al.
Published: (2021-01-01) -
Corrigendum: Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus
by: Isabel Kinney Ferreira De Miranda Santos, et al.
Published: (2020-11-01)